Table 4.
Effect of CCKR antagonists on the expression of c-Fos in fed rats treated with 2-deoxyglucose (2-DOG)
| Treatment | PVN | PVNp | NTS |
|---|---|---|---|
| Vehicle+vehicle | 43.3±11.1 (5) | 15.3±2.9 (5) | 6.5±1.5 (5) |
| Vehicle+2-DOG | 2210.0±269.7** (5) | 236.3±19.3** (5) | 119.7±8.4** (5) |
| SR-27,897+vehicle | 64.7±12.7 (4) | 21.0±3.5 (4) | 4.5±0.9 (4) |
| SR-27,897+2-DOG | 113.0±39.9 (5) | 23.3±3.9 (5) | 31.3±4.7*(5) |
| L-365,260+Vehicle | 86.7±3.7 (3) | 26.3±5.7 (3) | 4.0±0.9 (3) |
| L-365,260+2-DOG | 2732.0±338.7 (5) | 224.0±15.4 (5) | 130.7±6.1 (5) |
Values are mean±s.e.m. from 3–5 animals. For each animal, 4–6 sections containing the area were counted and an average value obtained. The effect of SR-27,897 (0.3 mg kg−1) was significant in total PVN and also in parvocellular PVN (**P<0.01, compared to vehicle+vehicle, SR-27,897+vehicle and SR-27,897+2-DOG groups; Newman–Keuls' test). In the NTS, SR-27,897 significantly decreased c-FOS expression (**P<0.01, compared to vehicle+vehicle, SR-27,897+vehicle and SR-27,897+2-DOG groups; *P>0.05 compared to vehicle+vehicle, SR-27,897+vehicle groups; Newman–Keuls' test). The number within parentheses corresponds to the number of animals used.